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Abstract
Importance—The current literature focuses on mortality among children younger than five 
years. Comparable information on non-fatal health outcomes among these children is scarce. 
Moreover, there has been little systematic data collection and reporting on both the fatal and non-
fatal burden of diseases and injuries among older children and adolescents.
Objective—To determine levels and trends in the fatal and non-fatal burden of diseases and 
injuries among younger children (<5 years), older children (5-9 years) and adolescents (10-19 
years) between 1990 and 2013 in 188 countries from the Global Burden of Disease (GBD) 2013 
study.
Design—Data from vital registration, verbal autopsy, maternal and child death surveillance, and 
other sources covering 14,244 site-years (the number of years for which cause of death data were 
available for a particular geographic area such as a country or demographic surveillance site) from 
1980 through 2013 were used to estimate cause-specific mortality. Data from 35,620 
epidemiological sources (mainly covered from 1990 to 2013) were used to estimate the prevalence 
of the diseases and sequelae included in the GBD. Cause-specific mortality for most causes was 
estimated using the Cause of Death Ensemble model strategy. For some infectious diseases (e.g., 
HIV/AIDS, measles, hepatitis B) where the disease process is complex or the cause of death data 
were insufficient or unavailable, we used natural history models. For most non-fatal health 
outcomes, DisMod-MR 2.0, a Bayesian meta-regression tool was used to meta-analyze the 
epidemiological data to generate prevalence and incidence estimates.
Results—Of the 7.7 (95% uncertainty interval (UI): 7.4-8.1) million deaths among children and 
adolescents globally in 2013, 6.3 million occurred among younger children, 0.48 million among 
older children, and 0.97 million among adolescents. In 2013, lower respiratory infections were the 
leading cause of death among younger children (905,059 deaths, UI: 810,304 - 998,125 ), 
diarrheal diseases among older children (38,325 deaths, UI: 30,365 - 47,678), and road injuries 
among adolescents (115,186 deaths, UI: 105,185 - 124,870). Iron deficiency anemia was the 
leading cause of years lived with disability among children and adolescents affecting 619 (UI: 618 
- 621) million prevalent cases in 2013. Large between-country variations exist in the trends in 
mortality from leading causes among children and adolescents. Developing countries with rapid 
declines in all-cause mortality between 1990 and 2013 also experienced large declines in mortality 
for most leading causes of death during the same period, whereas for countries with the slowest 
declines in all-cause mortality there was either a stagnant or an increasing trend in most of the 
leading causes of death. In 2013, Nigeria had about 4% of the world’s children and adolescents but 
a 12% share of global lower respiratory infections deaths and a 38% share of global malaria 
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deaths. India had nearly 20% of the world’s child and adolescent population but 33% of the 
world’s neonatal encephalopathy deaths. Half of world’s diarrheal deaths among children and 
adolescents occurred in just five countries: India, Democratic Republic of the Congo, Pakistan, 
Nigeria, and Ethiopia which together represented 30% of the world’s pediatric population in 2013.
Conclusions and Relevance—Understanding the levels and trends, as well as geography, of 
the leading causes of death and disability among children and adolescents is critical to guide 
investment and inform policies. Monitoring these trends over time is also key to understanding 
where interventions are having an impact, and where more attention is needed. Proven 
interventions exist to prevent diarrheal and respiratory diseases, neonatal conditions, iron 
deficiency anemia, and road injuries, which are leading causes of unnecessary death and disability 
among children and adolescents. The findings presented here show that these and other available 
interventions are underutilized and point to where more attention is needed.
Introduction
The current literature focuses on mortality rates and time trends among children younger 
than five years. There is little comparable information on the fatal and non-fatal burden of 
diseases and injuries among older children and adolescents. Children and adolescents 
constitute about a third of the world's population and their health status is important for 
every country and society.
Global mortality rates among younger children (< 5 years old) have been declining since 
1990 but striking variations in both the levels and trends exist across countries.1,2 For 
example, the number of under-five deaths per 1000 live births varied from 2.3 (95% 
uncertainty interval (UI): 1.8-2.9) in Singapore to 152.5 (95% UI: 130.6 to 177.4) in Guinea-
Bissau in 2013.2 The annualized rates of change in mortality of younger children for 
1990-2013 varied from -6.8% in Oman to 0.1% in Zimbabwe, and only 27 out of 138 
developing countries are estimated to achieve the target of the Millennium Development 
Goal 4 of a two-thirds reduction of 1990 mortality levels by 2015 (equivalent to an 
annualized rate of change of -4.4%).2 Although between-country variations in mortality 
among younger children have been reported, information on non-fatal health outcomes 
among these children is scarce. Moreover, there has been little systematic data collection and 
reporting on the fatal and non-fatal burden of diseases and injuries among older children and 
adolescents. Knowing the current burden and trends of the leading causes of death and 
disability in these age groups is critically important to shed light on areas that need more 
attention. In this study, we identified levels and trends in the fatal and non-fatal burden of 
diseases and injuries among younger children (<5 years), older children (5-9 years) and 
adolescents (defined by the United Nations as those aged 10-19 years3) for 1990-2013 in 
188 countries based on the results from the Global Burden of Disease 2013 study.
Methods and data sources
Detailed methods of the Global Burden of Disease (GBD) study have been published 
elsewhere1,4–6 and we provide only a brief description here. The study components relevant 
to the present paper are shown in eFigure 1.
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Cause-specific mortality was estimated using a database of vital registration, verbal autopsy, 
maternal and child death surveillance, and other sources covering 14,244 site-years (the 
number of years for which cause of death data were available for a particular geographic 
area such as a country or demographic surveillance site) from 1980 to 2013.1 Of the 14,244 
site-years, 5039 site years were from vital registration systems, 3860 from cancer registry, 
1798 from sibling history, 1433 from police records, 1430 from surveillance, 538 from 
verbal autopsy, and 146 from other sources including surveys, census, hospital, and burial or 
mortuary. The quality and comparability of the cause of death data were assessed and 
enhanced through multiple steps which have been reported in detail previously.1 Sample key 
steps include developing more than 100 maps to convert causes of death observed in the raw 
data to the GBD 2013 cause list, and identifying deaths being assigned to ill-defined or 
intermediate rather than underlying causes of death, which were redistributed to more 
specific underlying causes.1,7 Moreover data that were reported in aggregated categories 
were split into estimates of age-sex-specific deaths using the observed global pattern of 
relative risks of death for a cause by age and sex and the local age-sex distribution of the 
population.7 Country-specific data sources and citations for each cause and data before and 
after redistribution are shown in the online data visualization of the cause of death database 
at http://vizhub.healthdata.org/cod/. For most causes, we used the Cause of Death Ensemble 
model (CODEm) strategy1,7–9 which has been widely used for generating global health 
estimates. The CODEm strategy evaluates a large number of potential models that apply 
different functional forms (mixed effects models and space-time Gaussian Process 
Regression models) to mortality rates or cause fractions with varying combinations of 
predictive covariates. An ensemble of models that performs best on out-of-sample predictive 
validity tests is selected for each cause of death. For some infectious diseases (e.g., HIV/
AIDS, measles, hepatitis B) where the disease process is complex or the cause of death data 
were insufficient or unavailable, we used natural history models (i.e., models developed 
based on the natural history of diseases). For example, the natural history model for HIV/
AIDS took into consideration the nature of HIV epidemics in particular countries, and HIV 
mortality rates among those on and those off antiretroviral therapy, which were not captured 
in the cause of death data.10 Years of life lost due to premature mortality (YLLs) were 
calculated by multiplying the number of deaths at each age by a standard life expectancy at 
that age.1,7
The prevalence of diseases and their disabling consequences, called sequelae in the GBD, 
were estimated using an epidemiological database compiling data from systematic reviews 
on prevalence, incidence, remission, mortality risk and severity distributions of the diseases 
and injuries included in the GBD. There were 35,620 data sources (mainly covered from 
1990 to 2013) that include studies published in the scientific literature, nationally-
representative household surveys, antenatal clinic surveillance data, disease notifications, 
disease registries, hospital admissions data, outpatient visit data, population-based cancer 
registries, and other administrative data. Household surveys including the Demographic and 
Health surveys, Multiple Indicator Cluster Surveys, Living Standards Measurement Studies, 
Reproductive Health Surveys, and other national health surveys included in the Global 
Health Data Exchange were systematically screened for relevant data. For some diseases 
(e.g. measles and pertussis), case notifications reported to the World Health Organization up 
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to 2013 were used as input data. A full list of citations for sources organized by country are 
available in the appendix of a previous GBD paper (pp 97–653).5 Epidemiological data for 
most causes were meta-analyzed with DisMod-MR 2.0,5 a Bayesian meta-regression tool, 
which adjusts for variations in study methods between data sources and enforces consistency 
between data for different parameters, such as incidence and prevalence. The tool evaluates 
all the data through a geographical cascade of four levels (global, super-region, region, and 
country). At first, all data in the world are evaluated to estimate the fixed effects on age, sex, 
study-level and country-level covariates and the random effects for countries, regions and 
super-regions (we grouped regions into seven super-regions for analytical purposes11). The 
outputs of the global level are then used as prior information for the next, super-region level 
of the cascade. After fitting the model to each super-region’s data, the results are fed as 
priors to the region-specific fits and finally, region fits are used as a prior when modelling a 
country’s results for a particular time period. For countries and time periods for which little 
or no data are available, the estimation is facilitated by country characteristics and random 
effects on super-region, region and country. For this purpose, a database of country 
covariates for 93 topic areas and 242 variants was created, using data from household 
surveys, censuses, official reports, administrative data, and systematic reviews.1,5 The 
sources and imputation methods used to generate time series for the covariates have been 
reported previously.1 DisMod-MR 2.0 also allows the user to add strong prior knowledge on 
the age pattern and/or epidemiological parameters including incidence, remission and excess 
mortality rate. For example, major depressive disorder cannot be detected at very young 
ages, and we set a prior of zero incidence in children younger than 4 years. The assumptions 
and priors by individual condition have been reported in the appendix of a previous GBD 
paper (pp 654–684).5 Years lived with disability (YLDs) were computed by multiplying the 
prevalence of each sequela by a disability weight.5 Since we applied disability weights to 
prevalence in calculating YLD, the most prevalent cause of disability (defined as any 
departure from full health) is not necessarily the leading cause of YLD. For instance, mild 
vision impairment and caries are very common but cause relatively little disability.
Disability weights for a set of 235 health states were estimated by pair-wise comparison 
methods presenting pairs of lay health state descriptions to respondents in surveys conducted 
among the general population in nine countries and an open web-based survey.12 Each of 
the 2337 sequelae defined for 301 diseases and injuries mapped to one or a combination of 
the 235 health states. Sequelae are the direct consequences of disease or injury.11 Sequelae 
that are common across different diseases or injuries are called health states.11 For example, 
severe anemia due to malaria is a sequela that shares the health state of severe anemia with a 
number of other diseases such as hookworm disease and maternal hemorrhage. Disability-
adjusted life-years (DALYs) were computed as the sum of YLLs and YLDs for each 
country, age, sex and year. A full list of causes of death and disability and the corresponding 
ICD codes have been reported in previous GBD papers.1,5
The GBD classifies countries into developed (Australasia, North America, all of Europe, 
Brunei, Japan, Singapore and South Korea) and developing (all other countries) rather than 
using the World Bank income classification of low, middle and high income countries. As 
the income status of a country may change over time, it makes reporting on time series for 
country groupings with a varying composition more difficult. Although we realize that the 
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inclusion of some countries in either developed or developing is controversial, we have 
opted to use the GBD classification in this paper as it illustrates important differences in the 
levels and trends of mortality and DALY rates between the two sets of countries.
Results
Global mortality and leading causes of death in 2013
In 2013, there were 7.7 (95% UI: 7.4-8.1) million deaths among children and adolescents 
globally, of which 6.28 million occurred among younger children, 0.48 million among older 
children, and 0.97 million among adolescents (Table 1a & b, eTable 1-4).
Among all children and adolescents, the leading causes of death were predominantly those 
common in younger children as shown in Figures 1a and b and Figure 2, because of the large 
share of deaths in children younger than five years. The leading causes of death among 
younger children globally in 2013 were lower respiratory infections (905,059 deaths, UI: 
810,304 - 998,125), preterm birth complications (742,381 deaths, UI: 591,348 - 910,767), 
neonatal encephalopathy following birth trauma and asphyxia (643,765 deaths, UI: 515,010 
- 760,486), malaria (586,844 deaths, UI: 451,969 - 756,864), and diarrheal diseases (519,666 
deaths, UI: 438,795 - 593,675) (Table 1b, eTable 1, Figure 1b). These five causes accounted 
for 3.4 million deaths or 54% of all deaths among children younger than five years. Five 
other causes accounted for an additional 24% of deaths: congenital anomalies (495,319 
deaths, UI: 424,788 - 590,319), neonatal sepsis (366,041 deaths, UI: 233,155 - 510,770), 
other neonatal disorders (276,231 deaths, UI: 219,603 - 350,681), protein-energy 
malnutrition (225,906 deaths, UI: 168,497 - 280,129) and meningitis (141,952 deaths, UI: 
105,060 - 182,518) (Table 1b, eTable 1). The leading cause of death among younger children 
in each country in 2013 is shown in a map (eFigure 2). Lower respiratory infections, 
malaria, and diarrhea were the prevailing leading causes of death in sub-Saharan African 
countries. Lower respiratory infections were also the leading cause for some countries in 
Asia. Neonatal encephalopathy was the most common cause of death in some South Asian 
countries. Preterm birth complications and congenital anomalies were the leading causes of 
death among countries in North America, Australasia, Europe, East Asia, and most countries 
in Latin America and the Caribbean.
Among older children, the most common cause of death in 2013 was diarrheal diseases 
(38,325 deaths, UI: 30,365 - 47,678), followed by lower respiratory infections 
(37,431deaths, UI: 30,713 - 44,837), road injuries (36,577 deaths, UI: 31,097 - 41,896), 
intestinal infectious diseases (mainly typhoid and paratyphoid) (36,110 deaths, UI: 20,561 - 
57,277), and malaria (35,212 deaths, UI: 26,187 - 46,691) (eTable 2, eFigure 3). These five 
causes accounted for 181 thousand deaths or 39% of deaths among 5-9 year old children. 
Five other causes accounted for an additional 23% of deaths: drowning (31,500 deaths, UI: 
25,452 - 42,630), HIV/AIDS (28,211 deaths, UI: 26,407 - 30,307), hemoglobinopathies 
(20,229 deaths, UI: 6,077 - 42,394), congenital anomalies (17,508 deaths, UI: 14,677 - 
20,722), and meningitis 13,577 deaths, UI: 10,777 - 16,863) (eTable 2). Country-specific 
leading causes of death among children aged 5-9 years are shown in eFigure 4. For countries 
in North America, Latin America and Caribbean, and Australasia, road injuries were the 
leading cause of death while drowning was the most common cause of death in most 
Page 5
JAMA Pediatr. Author manuscript; available in PMC 2016 October 24.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
countries in Eastern Europe, East Asia and South East Asia. Intestinal infectious diseases 
and lower respiratory infections were the leading causes for countries in South Asia while 
diarrheal diseases, HIV/AIDS and malaria were the leading causes for countries in sub-
Saharan Africa.
Among adolescents, the leading cause of death in 2013 was road injuries (115,186 deaths, 
UI: 105,185 - 124,870), followed by HIV/AIDS (75,564 deaths, UI: 69,254 - 82,629), self-
harm (59,114 deaths, UI: 47,914 - 70,864), drowning (51,013 deaths, UI: 43,533 - 68,179), 
and intestinal infectious diseases (44,171 deaths, UI: 24,318 - 72,643) (eTable 3, eFigure 5). 
These five leading causes accounted for 34% of all deaths in this age group. Another five 
causes contributed an additional 17% of all deaths: interpersonal violence (38,300 deaths, 
UI: 27,452 - 45,009), lower respiratory infections (36,190 deaths, UI: 31,124 - 42,361), 
diarrhea (32,616 deaths, UI: 26,725 - 38,766), malaria (30,764 deaths, UI: 25,003 - 38,940), 
and tuberculosis (29,257 deaths, UI: 23,880 - 34,091) (eTable 3). Country-specific leading 
causes of death among adolescents in 2013 are shown in eFigure 6. Injury related deaths 
were the leading causes in most countries except for those in sub-Saharan Africa where 
HIV/AIDS was the dominant leading cause of death. Self-harm was the most common cause 
of death for some parts of Asia and Eastern Europe.
Contributions to global child and adolescent deaths according to population proportion
Table 1a shows the number of deaths and age-standardized mortality rates for the 10 leading 
causes among children and adolescents at the global level and in the 50 countries with the 
largest child and adolescent populations. In 2013, there were 2.5 billion children and 
adolescents in the world, and the 50 countries represented 73% of this population (eTable 5). 
In 2013, Nigeria had about 4% of the world’s children and adolescents (eTable 5) but a 12% 
share of global lower respiratory infections deaths and a 38% share of global malaria deaths 
(Table 1a). India had nearly 20% of the world’s child and adolescent population but 33% of 
the world’s neonatal encephalopathy deaths. Half of world’s diarrheal deaths among 
children and adolescents occurred in just five countries: India, Democratic Republic of the 
Congo, Pakistan, Nigeria, and Ethiopia which together represented 30% of the world’s 
pediatric population in 2013 (Table 1a, eTable 5).
Mortality time trends
The global decline in mortality between 1990 and 2013 was faster among younger (annual 
percent change (APC), -3.0%) and older children (APC, -2.9%) than adolescents (APC, 
-1.6%) (eTables 6-8). The corresponding APC figures in developing countries were -3.1, 
-3.0, and -1.7% and those in developed countries were -3.5, -3.9, and -2.5% respectively 
(eTables 6-8).
Among children younger than five years, countries in which all-cause mortality declined 
rapidly experienced these large declines in most of the leading causes of death (eTable 6). 
For example, Oman, China and Maldives, the three countries with fastest declining under-
five mortality rates, showed an annual reduction of 5.6% or greater in mortality from at least 
6 of the 10 leading causes of death (eTable 6). Countries with the slowest declines (Vanuatu, 
Fiji, Swaziland, Lesotho, and Zimbabwe) showed either a stagnant or an increasing trend in 
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most of the 10 leading causes (eTable 6). Similarly, among older children and adolescents, 
countries with a rapid decline in all-cause mortality experienced greater declines for most of 
the leading causes of death in these age groups (eTables 7-9).
Global YLDs and prevalence of the leading causes of disability
In 2013, disability caused 135.6 million YLDs among children and adolescents, of which 
26.4 million affected children younger than five years, 29.6 million affected older children, 
and 79.6 million affected adolescents (data not shown in table).
Leading causes of YLD largely overlapped among the three age groups. Iron deficiency 
anemia was the most common cause of YLD in both younger and older children and 
adolescents in 2013 (Table 2, eTable 10-13). The 50 countries with the largest child and 
adolescent population contributed to 86% of global iron deficiency anemia cases in this 
population (Table 2). India contributed the largest number of cases (147.9 million), followed 
by China (75.7 million) and Nigeria (24.7 million). The prevalence of iron-deficiency 
anemic children and adolescents was highest in Afghanistan (41%), followed by Yemen 
(39.8%) and Senegal (38.5%) (Table 2, eTable 13).
Skin diseases were the second leading cause of YLD among children and adolescents in 
2013 (Table 2). Younger and older children were most commonly affected by viral skin 
diseases and dermatitis, whereas adolescents were mainly affected by acne vulgaris(data not 
shown in table) . Depressive disorders were the third most common cause of YLD among 
children and adolescents, with the prevalence in adolescents being 4 times as high as that in 
older children (2.8% versus 0.7%) (Table 2, eTable 11 & 12).
Among other leading causes of YLD among children and adolescents, conduct disorder, 
anxiety disorders, low back and neck pain, and migraine mainly affected older children and 
adolescents, whereas sense organ diseases and hemoglobinopathies affected all three age 
groups (Table 2, eTable 10-12). Among sense organ diseases, uncorrected refractive error 
and hearing loss were the most frequently occurring causes in all three age groups (data not 
shown in table). The country-year-age-sex specific distributions of YLDs for each cause and 
their sub-categories are viewable in an interactive online visualization tool at http://
vizhub.healthdata.org/gbd-compare.
DALYs among children and adolescents
Figure 3 shows DALY rates for leading causes among males and females aged 0-19 years at 
the global level and in the 50 countries with the largest child and adolescent populations. 
Age-group specific leading causes of DALYs are shown in eFigures 7-9. The rankings of 
leading causes of deaths and DALYs are similar if the percent contribution to the disease 
burden by mortality is high, which is especially the case for the main conditions affecting 
younger children (Figure 1b and eFigure7). Sex differences were small in younger children 
but larger in some of the causes among adolescents. For instance, transport injuries, 
drowning and interpersonal violence among adolescent boys were much higher than among 
adolescent girls (eFigure 9). The most striking sex differences were observed in Venezuela, 
Colombia and Brazil for interpersonal violence (eFigure 9). Maternal disorders were 
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common causes of DALYs among adolescent girls in sub-Saharan African and South Asian 
countries (eFigure 9).
Time trends in DALYs
Among all children and adolescents, the leading causes of DALYs were dominated by those 
common in children younger than five years (Figure 4a & b), who had the greatest share of 
deaths. Lower respiratory infections remained the leading cause of DALYs among children 
younger than five years in both 1990 and 2013, but the number and rate of DALYs declined 
over the 23 years by 58% and 59% respectively (Figure 4b). Preterm birth complications and 
neonatal encephalopathy rose in rank (from 3rd and 4th to 2nd and 3rd respectively) because 
of their relatively slower rates of decline than diarrhea, which dropped from 2nd to 5th, with 
a 67% decrease in DALY rates (Figure 4b). The rate for measles also notably declined (from 
8th to 14th), with an 84% decrease in DALY rates between 1990 and 2013 (Figure 4b).
Among older children and adolescents, iron deficiency anemia remained the leading cause 
of DALYs in both 1990 and 2013, with a modest decrease in the number and rate of DALYs 
over the 23 years (eFigure 10 & 11). The rank of HIV/AIDS increased from 101 to 6 among 
adolescents, 78 to 10 among older children, and 33 to 17 among younger children between 
1990 and 2013, with a statistically significant increase in both DALY counts and rates 
(Figure 4b, eFigure 10 & 11). Full details of the results by age, sex, geography, and time 
period can be viewed in the online interactive visualization tool (http://
vizhub.healthdata.org/gbd-compare).
Discussion
This is the first of a series of annual updates to identify levels and trends in the fatal and 
non-fatal burden of diseases and injuries among children and adolescents at the country-
level. Of the 7.7 million deaths among children and adolescents globally in 2013, about 80% 
occurred among younger children. Of the 135.6 million YLDs among children and 
adolescents in 2013, about 60% of the YLDs were contributed by adolescents. Leading 
causes of death among children and adolescents in 2013 fell into four main categories: 
neonatal, congenital, infectious diseases and injuries. Developing and developed countries 
had both similarities and differences in the leading causes of death. In both sets of countries, 
preterm birth complications and congenital anomalies were common causes of death among 
children younger than five years, whereas injuries were major killers of adolescents. 
Infectious diseases including lower respiratory infections, neonatal sepsis, malaria, diarrheal 
diseases, HIV/AIDS, typhoid and tuberculosis remained major challenges in developing 
nations. In several countries, vaccine-preventable diseases such as measles and pertussis 
were still among the 10 leading causes of death, indicating a need to strengthen 
immunization programs in those countries. Leading causes of YLD largely overlapped 
among the three age groups, with iron deficiency anemia and skin diseases being the first 
and second common causes of YLD among children and adolescents.
Trends from the leading causes of death in younger children varied widely across countries. 
Countries with greater declines in all-cause child mortality tended to have a rapid decline in 
mortality rates for most of the main causes of death, suggesting that general improvements 
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in health services and public health interventions for a wide range of health problems (e.g., 
improved management of childhood illnesses, immunization, mass distribution of 
insecticide-treated bed nets, and improved access to prenatal, obstetric and postnatal care) 
rather than single disease programs determine success. The declines in poverty levels and 
improvements in living conditions over time might have also contributed to the declines in 
mortality. Countries with slowly declining or stagnant trends in all-cause under-five 
mortality generally showed similar trends in mortality rates for the leading causes. Most of 
these deaths, especially in developing countries, could be prevented by a concerted response 
from health systems and public health interventions.
The typical leading causes of death in younger children such as lower respiratory infections 
and diarrhea were also common causes of death for older children in many developing 
countries, indicating that interventions targeting the former should extend to cover the latter. 
Mortality and DALY rates for lower respiratory infections and diarrhea declined over the 
past 23 years, but they were still among the top five causes for both younger and older 
children in 2013. In fact, lower respiratory infections were the first leading cause of death 
among younger children, whereas diarrhea was the most common cause of death among 
older children. These deaths are largely avoidable through case identification and proper 
management and prevention of risk factors. Unsafe water, sanitation and hand washing 
practices are largely responsible for diarrheal deaths, whereas household air pollution and 
ambient air pollution are important risk factors for deaths from lower respiratory infections 
in both younger and older children, with undernutrition being an additional key risk factor 
for these two diseases among younger children.13 Proven interventions14–16 exist to reduce 
exposures to these risk factors but uptake is insufficient.
The decline in all-cause mortality rates among adolescents between 1990 and 2013 was 
slower than that among younger and older children. Road injuries were the leading cause of 
death among adolescents globally, with a stagnant or increasing trend in most developing 
countries. Many countries inadequately implement proven road safety practices (e.g. safety 
measures for road users and vehicles, road infrastructure and post-crash care)17. With 
increasing motorization, these trends are likely to worsen unless decisive action is taken.
Self-harm was the second most common cause of injury-related death among adolescents. 
While the most common suicidal methods differ across geography, restricting access to 
common lethal means has proven to be effective in reducing suicide rates.18,19 For 
example, pesticide ingestion is a commonly used method of suicide among young people in 
developing countries.20 Prohibition of toxic pesticides in Sri Lanka and South Korea has 
been shown to reduce both the overall and method specific suicide rates.21,22 National 
suicide prevention strategies can play a role in preventing suicide but such strategies are 
lacking in many countries worldwide.19 Mental and substance use disorders contributed to 
two-thirds of all suicide DALYs in the world, indicating the importance of early detection 
and effective management of these disorders as part of suicide prevention strategies.23
Drowning was among the 10 leading causes of death among older children and adolescents 
and the 14th leading cause of death among younger children in 2013. Lack of barriers to 
water sites and absence of close supervision are key risk factors for drowing among younger 
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children in both developing and developed countries.24,25 Older children and adolescents 
usually drown during non-recreational or daily activities in developing countries, but during 
recreational activities in developed countries.26 Risk of death from drowning is especially 
high in rural areas in developing countries, where unfenced water sources are close to the 
homes, without any emergency medical care facilities or capacity to perform resuscitation 
for the drowning child.24,26 In developed countries, failure to wear life jackets during 
boating activities and alchol use among adolescents during water related recreation are 
among the risk factors for drowning.25,26
In addition to injuries, infectious diseases were important causes of death among adolescents 
in developing countries, especially HIV/AIDS, lower respiratory infections, intestinal 
infectious diseases, diarrhea, malaria, and tuberculosis. The mortality rates for all these 
diseases except HIV/AIDS are decreasing. Deaths from HIV/AIDS among adolescents are 
concentrated in sub-Saharan Africa and have been increasing since 1990. This trend differs 
from that in all age groups, where it increased after 1990, peaked around 2005 and then 
declined steadily after antiretroviral treatment became more widely available.10 Low rates 
of HIV testing, an important step toward HIV treatment, and poor access to antiretroviral 
treatment among adolescents,27 might explain some of the increases in HIV/AIDS mortality 
in this age group. Although much emphasis has been placed on prevention of HIV infections 
among adolescents, little attention has been given to the care of those who were infected 
during infancy.28 High rates of children orphaned by HIV/AIDS, the necessity of guardian 
consent to undergo HIV testing, and the lack of clear policies and guidance regarding 
consent and HIV testing among minors are among the barriers to HIV testing and care for 
older children and adolescents.28,29
Leading causes of disability among all children and adolescents were dominated by causes 
common in adolescents because of a larger share of YLDs by this age group. Iron deficiency 
anemia, the largest cause of disability, however, is common in both younger and older 
children and adolescents. The high demand of nutritients for growth, blood loss during 
menstruation in adolescent girls, and hookworm infections (especially in developing 
countries) put children and adolescents at risk for this deficiency. Although iron 
supplementation is effective, challenges exist in terms of distribution, cost and compliance.
30 Other cost-effective interventions exist, including food fortification and biofortification of 
crops, with the latter being a way of reaching rural populations with limited access to 
marketed fortified foods.30,31
Compared to changes in the causes of mortality which are generally showing decreasing 
rates in all age groups,1 there are smaller changes, if at all, in the prevalence of many causes 
of disability (data not shown). The slow decline in disabling conditions is not specific to 
children and adolescents but a more common feature across the age span.5 Major depressive 
disorder, conduct disorder and anxiety disorders were major causes of disability among 
older children and adolescents in 2013. Whereas identification and treatment of these 
disorders are important, prevention of modifiable risk factors such as child abuse and 
neglect, bullying and intimate partner violence, should also be a priority.32 Other common 
causes of disability such as low back and neck pain, migraine, and skin disorders were also 
showing little change. Musculoskeletal disorders have drawn more attention since the GBD 
Page 10
JAMA Pediatr. Author manuscript; available in PMC 2016 October 24.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
2010, but there is still limited policy discussion on the approaches to deal with and/or 
prevent the leading causes of low back and neck pain.5,33,34 Migraine and other headache 
disorders generally attract low health-care priority despite the disability attributed to them.35
Limitations
The general limitations of the GBD study also apply to this report. These limitations have 
been discussed widely and in detail in the published GBD 2013 papers and we summarized 
the relevant limitations here.1,2,5,6,10 First, there were variations in the instrument used for 
collection of verbal autopsy data, which might reduce the between-country comparability of 
cause of death data. Moreover, the quality of the medical certification of causes of death 
(e.g. diagnostic accuracy), might have also influenced our estimates. Second, although 
redistribution of ill-defined or intermediate causes to specific underlying causes improved 
the comparability of cause of death data, it could yield results different from official 
statistics of countries. This could happen because the redistribution used global or regional 
algorithms, which did not pick up variations across countries in terms of certification 
practices or the timing of implementation of coding rules. We plan to use more country-
specific redistribution algorithms in future rounds of the GBD. Third, the fact that the sum of 
cause-specific mortality estimates must equal all-cause mortality for a particular country, 
age, sex, and year, is a strength of the GBD approach, but it also has a limitation. Causes of 
death with very wide UIs (e.g. hemoglobinopathies) tend to be adjusted downwards relative 
to causes with narrower UIs. Fourth, in general, the epidemiological data coverage for the 
period 2006-2013 was relatively lower than the period 1998-2005 although there were 
variations by disease. For example, the percentages of countries that have epidemiological 
data on low back and neck pain for the period 1998-2005 and 2006-2013 were 41.5% and 
13.3% respectively. The lower coverage for the latter might be explained by the lag in data 
collection, analyses and publications.5 For some diseases such as tuberculosis, the data 
coverage is higher for the recent years (91.5% for the period 1998-2005 versus 98.4% for 
2006-2013). A systematic quantification of the geographical and temporal coverage of the 
input epidemiological data by cause has been reported in detail previously.5 Making 
estimates for every country over time is challenging especially for those with little or no 
data. We had to make use of sophisticated modeling techniques to borrow strength across 
geography and covariates to help predict for countries and years with sparse data. The lack 
of data for a particular geography is reflected by wider uncertainty intervals. Finally, for 
some causes of disability, long term consequences in later years of life are not reflected in 
this paper. For example, long term impairments due to preterm birth complications, neonatal 
encephalopathy and Down’s syndrome after age 19 were not counted in the DALY rankings 
since we focused only on the burden of disease experienced by those aged 0-19 years.
Conclusions
Understanding the levels and trends, as well as geography, of the leading causes of death and 
disability among children and adolescents is critical to guide investment and inform policies. 
Monitoring these trends over time is also key to understanding where interventions are 
having an impact, and where more attention is needed. The vast majority of deaths in 
children and adolescents are preventable. Proven interventions exist to prevent diarrheal and 
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respiratory diseases, neonatal conditions, iron deficiency anemia, and road injuries, which 
result in some of the highest burdens of unnecessary death and disability among children and 
adolescents. The findings presented here show that these and other available interventions 
are underutilized and point to where more attention is needed. The findings point out that 
proven health interventions could save millions of lives. Despite the general decline in 
mortality, the speed of the decline could still be ‘faster’.
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• In this study, we identified the fatal and non-fatal burden of diseases 
and injuries among younger children (<5 years), older children (5-9 
years) and adolescents (10-19 years) for 1990-2013 in 188 countries.
• Of the 7.7 million deaths among children and adolescents globally in 
2013, 80% occurred among younger children. Of the 135.6 million 
years lived with disability among children and adolescents in the same 
year, 60% were contributed by adolescents.
• In 2013, lower respiratory infections were the leading cause of death 
among younger children (905,059 deaths), diarrheal diseases among 
older children (38,325 deaths), and road injuries among adolescents 
(115,186 deaths). Iron deficiency anemia was the leading cause of 
years lived with disability among children and adolescents affecting 
619 million prevalent cases in 2013.
• There is large variation in the distribution of deaths and disease burden 
between countries. For instance, in 2013, Nigeria had about 4% of the 
world’s children and adolescents but a 12% share of global lower 
respiratory infections deaths and a 38% share of global malaria deaths. 
Also, half of world’s diarrheal deaths among children and adolescents 
occurred in just five countries: India, Democratic Republic of the 
Congo, Pakistan, Nigeria, and Ethiopia which together represented 
30% of the world’s pediatric population in 2013.
• Detailed information on causes of death and non-fatal health outcomes 
in children and adolescents by age, sex, and country over time is an 
essential input into policy decision making on resource allocation to 
disease prevention and treatment programs.
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Figure 1a. Top 25 Global Causes of Death for the Largest 50 Countries by Child and Adolescent 
Population, Both Sexes, Ages 0 to 19, 2013
Footnote (Figure 1a): Colors correspond to the ranking of the leading causes of death, with 
dark red as the most common cause and dark green as the least common cause for the 
location indicated. The numbers inside each box indicate the ranking.
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Figure 1b. Top 25 Global Causes of Death for the Largest 50 Countries by Child and Adolescent 
Population, Under 5, Both Sexes, 2013
Footnote (Figure 1b): Colors correspond to the ranking of the leading causes of death, with 
dark red as the most common cause and dark green as the least common cause for the 
location indicated. The numbers inside each box indicate the ranking.
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Figure 2. Top cause of death by country for ages 0 to 19, both sexes, 2013
Footnote (Figure 2): “Foreign Body” refers to “foreign body in lung and pulmonary 
aspiration”. “Neonatal Encephalopathy” refers to “neonatal encephalopathy following birth 
trauma and asphyxia”.
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Figure 3. Age-standardized DALY rate (per 100,000), ages 0 to 19, 2013
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Figure 4a. Top 25 global causes of DALYs, ages 0 to 19, both sexes, 1990 and 2013
Footnote 1 (Figure 4a): Causes connecting with lines show changes in ranks between 1990 
and 2013. The second column on the right-hand side shows the mean DALY counts. The 
third and fourth columns on the right-hand side show the median percent changes 
(calculated at the 1000 draw level) in the number and rates of global DALYs.
Footnote 2 (Figure 4a): *Changes that are statistically significant.
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Figure 4b. Top 25 global causes of DALYs, under 5, both sexes, 1990 and 2013
Footnote 1 (Figure 4b): Causes connecting with lines show changes in ranks between 1990 
and 2013. The second column on the right-hand side shows the mean DALY counts. The 
third and fourth columns on the right-hand side show the median percent changes 
(calculated at the 1000 draw level) in the number and rates of global DALYs.
Footnote 2 (Figure 4b): *Changes that are statistically significant.
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